Oral Chemotherapy With Trastuzumab Shows High Survival in Small HER2 Breast Tumors
A prospective phase II trial found that oral capecitabine combined with trastuzumab achieved a 97.3 percent five-year disease-free survival rate ...
A prospective phase II trial found that oral capecitabine combined with trastuzumab achieved a 97.3 percent five-year disease-free survival rate ...
The phase II ALTER-T001 trial demonstrated that neoadjuvant anlotinib yielded a 42.0 percent objective response rate and enabled conversion surgery ...
A single-arm phase II trial found that adding fluzoparib to neoadjuvant chemotherapy did not improve residual cancer burden grade 0/I ...
In the randomized phase II AdvanTIG-203 trial, adding the anti-TIGIT antibody ociperlimab to tislelizumab did not significantly improve response rates ...
A randomized phase II trial found that the 4CMenB meningococcal vaccine induced robust serum antibodies and modest mucosal IgG responses ...
A multicentre phase II trial found that co-administering the monoclonal antibody AZD7442 and a bivalent vaccine was well tolerated in ...
A multicenter phase II trial demonstrates that early infusion of abundant normal saline after intravenous thrombolysis improves 90-day functional recovery ...
In a groundbreaking advancement in the treatment of pancreatic adenocarcinoma, a novel clinical trial has emerged, reexamining standard therapeutic protocols ...
In the relentless pursuit of better outcomes for patients diagnosed with advanced osteosarcoma, a groundbreaking clinical investigation has emerged, potentially ...
A groundbreaking phase II clinical trial has unveiled promising results in the fight against advanced hepatocellular carcinoma (HCC) by combining ...
In a groundbreaking stride towards redefining treatment paradigms for muscle-invasive bladder cancer (MIBC), a multicenter phase II clinical trial is ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.